Bailard’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bailard’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,000	Closed	-$243K	–	622
2019 Q3	$243K	Sell	5,000 -46,000	-90%	-$2.4M	0.01%	440
2019 Q2	$2.68M	Sell	51,000 -12,900	-20%	-$741K	0.16%	124
2019 Q1	$3.38M	Buy	63,900 +9,000	+16%	+$442K	0.21%	102
2018 Q4	$2.25M	Buy	54,900 +22,000	+67%	+$824K	0.15%	131
2018 Q3	$1.25M	Sell	32,900 -7,600	-19%	-$337K	0.07%	195
2018 Q2	$1.83M	Sell	40,500 -1,000	-2%	-$45.5K	0.11%	170
2018 Q1	$2M	Sell	41,500 -31,200	-43%	-$1.74M	0.13%	163
2017 Q4	$2.86M	Buy	72,700 +27,000	+59%	+$1.01M	0.18%	130
2017 Q3	$1.42M	Hold	45,700	–	–	0.11%	147
2017 Q2	$1.25M	Buy	+45,700	New	+$1.36M	0.1%	160

Other funds holding GBT

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bailard's GBT Position: Q4 2019 in Review

Bailard sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2019, closing a stake of 5,000 shares — an estimated $243K sold.

Bailard first reported a position in GBT in Q2 2017 and held it in 10 quarters. The position peaked at $3.38M in Q1 2019. 234 funds tracked by Wall St. Rank hold GBT as of Q4 2019.

Bailard reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Bailard sold 5,000 Global Blood Therapeutics, Inc. shares in Q4 2019, an estimated $243K.
Bailard first reported a position in Global Blood Therapeutics, Inc. in Q2 2017 and held it in 10 quarters.
Bailard's Global Blood Therapeutics, Inc. position peaked at $3.38M in Q1 2019.
234 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2019.

Based on Bailard's 13F filing for Q4 2019, filed 31 Jan 2020.